Latest News about GILD
Recent news which mentions GILD
From Benzinga
From Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
March 11, 2022
Tickers
GILD
From Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
From Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
February 28, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
3 Pharma Stocks That Retired Investors Should Love
February 26, 2022
From Motley Fool
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
From InvestorPlace
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
From InvestorPlace
See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization
February 18, 2022
From Benzinga
Want To Collect $200 Every Month? Invest $49,334 in These 3 Stocks
February 18, 2022
From Motley Fool
These 3 Stocks Just Declared Dividend Raises
February 18, 2022
From Motley Fool
Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients
February 17, 2022
Tickers
GILD
From Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
From Benzinga
Hookipa Pharma Stock Surges On HIV Pact With Gilead
February 16, 2022
From Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
From Benzinga
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings
February 16, 2022
From Motley Fool
3 Biotech Stocks to Buy in February
February 16, 2022
From Motley Fool
Tracking Gilead's 4 Big Stories and a Lawsuit in 2022
February 15, 2022
From Motley Fool
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
From Benzinga
Is the FDA's Partial Hold Bad News for Gilead Investors?
February 12, 2022
From Motley Fool
If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today
February 11, 2022
Tickers
GILD
From Benzinga
Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron
February 11, 2022
Tickers
GILD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.